pantoprazole has been researched along with Cirrhosis, Liver in 7 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This observation further supports the notion that pantoprazole can induce acute hepatocellular hepatitis, and it strongly suggests that it may trigger acute cholangitis and autoimmune liver injury." | 7.88 | Pantoprazole-induced autoimmune chronic hepatitis. ( Larrey, D; Meunier, L; Pageaux, GP; Ursic-Bedoya, J, 2018) |
| "This observation further supports the notion that pantoprazole can induce acute hepatocellular hepatitis, and it strongly suggests that it may trigger acute cholangitis and autoimmune liver injury." | 3.88 | Pantoprazole-induced autoimmune chronic hepatitis. ( Larrey, D; Meunier, L; Pageaux, GP; Ursic-Bedoya, J, 2018) |
| " Following a single oral dose of 40 mg, Cmax is approximately 2." | 2.68 | Pharmacokinetics of pantoprazole in man. ( Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Steinijans, VW; Zech, K, 1996) |
| "In 84 consecutive cirrhotic patients, bacterial infection risk was prospectively assessed and related to PPI use." | 1.38 | Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. ( de Rooij, FW; Huisman, EJ; Renooij, W; Siersema, PD; van Erpecum, KJ; van Hoek, B; van Vlerken, LG, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Labenz, C | 1 |
| Kostev, K | 1 |
| Galle, PR | 1 |
| Wörns, MA | 1 |
| Labenz, J | 1 |
| Tanislav, C | 1 |
| Adarkwah, CC | 1 |
| Meunier, L | 1 |
| Ursic-Bedoya, J | 1 |
| Pageaux, GP | 1 |
| Larrey, D | 1 |
| Yang, SC | 1 |
| Chen, JC | 1 |
| Tai, WC | 1 |
| Wu, CK | 1 |
| Lee, CH | 1 |
| Wu, KL | 1 |
| Chiu, YC | 1 |
| Wang, JH | 1 |
| Lu, SN | 1 |
| Chuah, SK | 1 |
| Calcagno, A | 1 |
| Trentalange, A | 1 |
| Simiele, M | 1 |
| Marinaro, L | 1 |
| Patti, F | 1 |
| Tettoni, MC | 1 |
| Trentini, L | 1 |
| Di Perri, G | 1 |
| DʼAvolio, A | 1 |
| Bonora, S | 1 |
| Tsai, CF | 1 |
| Chen, MH | 1 |
| Wang, YP | 1 |
| Chu, CJ | 1 |
| Huang, YH | 1 |
| Lin, HC | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Su, TP | 1 |
| Lu, CL | 1 |
| van Vlerken, LG | 1 |
| Huisman, EJ | 1 |
| van Hoek, B | 1 |
| Renooij, W | 1 |
| de Rooij, FW | 1 |
| Siersema, PD | 1 |
| van Erpecum, KJ | 1 |
| Huber, R | 1 |
| Hartmann, M | 1 |
| Bliesath, H | 1 |
| Lühmann, R | 1 |
| Steinijans, VW | 1 |
| Zech, K | 1 |
1 trial available for pantoprazole and Cirrhosis, Liver
| Article | Year |
|---|---|
Pharmacokinetics of pantoprazole in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 1996 |
6 other studies available for pantoprazole and Cirrhosis, Liver
| Article | Year |
|---|---|
Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis.
Topics: Bacterial Infections; Case-Control Studies; Databases, Factual; Female; Germany; Humans; Liver Cirrh | 2020 |
Pantoprazole-induced autoimmune chronic hepatitis.
Topics: Chemical and Drug Induced Liver Injury; Cholangitis; Cholestasis; Female; Hepatitis, Autoimmune; Hum | 2018 |
The influential roles of antibiotics prophylaxis in cirrhotic patients with peptic ulcer bleeding after initial endoscopic treatments.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibiotic | 2014 |
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; | 2015 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Contro | 2017 |
Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Animals; Bacteria; Bacterial Infections; Cohor | 2012 |